Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy
Condition: Prostatic Hypertrophy, Benign
MeSH terms: Prostatic Hyperplasia; Hypertrophy
Intervention: Vardenafil (Levitra, BAY38-9456); Placebo
Intervention description: One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.; One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Intervention MeSH terms: Vardenafil Dihydrochloride
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 50.0
Sex: Male
Minimum age: 18 Years
Maximum age: 80 Years
Healthy volunteers: No

Summary:

      The greenlight laser has an absorption maximum which is exactly the same as for hemoglobin.
      In the presence of hemoglobin, its application causes vaporization of the tissue and this
      effect depends on the concentration of hemoglobin in the respective tissue. Therefore,
      increase of blood-flow in the tissue (here: prostate gland) should exert better efficacy of
      the laser application and consequently shortening of the required duration of laser
      application.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Men with benign prostate hypertrophy requiring surgical treatment

          -  Age up to 80 years

          -  Documented, dated, written Informed Consent

          -  Anesthesiologists agreement with swallowing 1 tablet one hour prior surgery

        Exclusion Criteria:

          -  Any unstable medical, psychiatric, or substance abuse disorder

          -  History of previous prostatectomy

          -  Patients suspect of prostate cancer

          -  Hereditary degenerative retinal disorder

          -  History of previous Non-arteric Anterior Ischemic Optic Neuropathy (NAION) episode or
             unilateral vision impairment

          -  Any cardiovascular condition

          -  History of myocardial infarction, stroke or life-threatening arrhythmia within the
             prior 6 months

          -  Uncontrolled atrial fibrillation/flutter at screening

          -  Severe chronic or acute liver disease

          -  Chronic hematological disease which may lead to priapism

          -  Bleeding disorder

          -  Significant active peptic ulceration

          -  Resting hypotension

          -  History of positive test for Hepatitis B surface antigen or Hepatitis C

          -  Symptomatic postural hypotension within 6 months of Visit 1

          -  Patients who subjectively or in the opinion of the investigator did not tolerate the
             initial dose of study medication well

          -  Subjects who are taking nitrates or nitric oxide donors

          -  Subjects who are taking androgens or anti-androgens

          -  Subjects who are taking potent inhibitors of cytochrome P4503A4

          -  Subjects who have received any investigational drug within 30 days of Visit 1

          -  Using of alpha-blockers during two days prior to first dosing of study medication and
             after ablation of prostate

          -  Use of inhibitors of 5-alpha reductase after ablation of prostate

          -  Subjects with serum creatinine clearance <30.0 mL/min

          -  Elevation of Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) >3
             times the upper limit of normal

          -  Subjects with known hypersensitivity to Vardenafil

          -  Subjects who are illiterate or unable to understand subject diaries

          -  Subjects who would be non-compliant with the study visit schedule